andere Bezeichnungen
- Reizdarmsyndrom (RDS)
Reizdarm
Reizdarmsyndrom ist eine Gruppe funktioneller Darmerkrankungen. Symptome des Reizdarmsyndroms sind Schmerzen oder Unwohlsein im Bauchraum zusammen mit einer Veränderung in den Stuhlgewohnheiten unter Ausschluss einer strukturellen oder biochemischen Ursache.
Hauptwirksame Cannabinoide
- CBD (Cannabidiol)
Studien/Artikel zur Behandlung von mit Cannabis-Medikation
- Cannabidiol in inflammatory bowel diseases: a brief overview.
- Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.
- Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
- Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
- Therapeutic potential of cannabinoid-based drugs.
- Cannabinoids and the gut: new developments and emerging concepts.
- Endocannabinoids and the gastrointestinal tract.
- Cannabinoids and gastrointestinal motility: animal and human studies.
- The Role of the Endocannabinoid System in the Brain-Gut Axis.
- Cannabidiol in inflammatory bowel diseases: a brief overview.
- Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.
- Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
- Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
- Therapeutic potential of cannabinoid-based drugs.
- Cannabinoids and the gut: new developments and emerging concepts.
- Endocannabinoids and the gastrointestinal tract.
- Cannabinoids and gastrointestinal motility: animal and human studies.
- The Role of the Endocannabinoid System in the Brain-Gut Axis.
- Cannabinoids and GI Disorders: Endogenous and Exogenous.
- Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans.
- The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients.
- Potential of plant-sourced phenols for inflammatory bowel disease.
- Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.
- Link Wikipedia (DE)
sonstiges Wissenswertes
BfArM Ausnahmgenehmigungen erteilt (vor der Gesetzesänderung im März 2017 in Deutschland gab es für Reizdarm Diagnosen Ausnahmegenehmigungen zur Behandlung mit Cannabis durch das Bundesinstitut für Arzneimittel und Medizinprodukte)
1 Kommentare